







Study title	An observational study to describe treatment patterns of patients with BRAFV600E mutant metastatic non-small cell lung cancer (OCTOPUS).
Disease 	Non-small cell lung cancer (NSCLC).
Treatment(s) observed 	First and second-line treatments for metastatic non-small cell lung cancer.
Participants 	Adult patients diagnosed with BRAFV600E mutant metastatic NSCLC (mNSCLC) who initiated a first systemic treatment from December 2017 and before study enrolment, or after study enrolment.
Study dates 	From 23 June 2022 to June 2025.
Study Locations 	France, Germany, Italy, Spain, United Kingdom.
<p>We do research to improve patient care. By participating in an observational study, one helps to answer important scientific questions for the benefit of all.</p>	

This document is a brief summary of a clinical study protocol. It is written in plain language for the general public, providing answers to the following questions:

- What is the purpose of the study?
- What are the objectives of the study and how are they evaluated?
- How is the study conducted?
- Who can take part in the study?

<p>What is the purpose of the study?</p>	<p>Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer diagnoses. Approximately 1-2% of patients affected by a NSCLC have a specific genetic mutation called BRAFV600E mutation.</p> <p>In a context of a lack of information, it would be useful for the future patients to provide an overview of diagnosis and treatment processes using data of patients already affected by this cancer.</p> <p>Therefore, the purpose of this study is to identify treatment patterns given to patients with mutated BRAFV600E mNSCLC and to describe the efficacy of treatments and patients' quality of life in routine practice.</p>
<p>What are the objectives of the study and how are they evaluated?</p>	<p>The primary objective of the study is to describe treatments patterns for first- and second- systemic treatments lines given to adult patients with BRAFV600E mNSCLC.</p> <p>The secondary objectives of OCTOPUS are to:</p> <ul style="list-style-type: none"> • Describe treatment patterns for subsequent treatment lines (beyond first- and second-line). • Describe demographic and clinical characteristics by collecting data such as age, gender, comorbidities, date of initial diagnosis... • Describe efficacy of treatments and assess the evolution of patients' quality of life through questionnaires.

	<ul style="list-style-type: none"> Describe side effects related to first- and second-line treatments.
How is the study conducted?	The schema depicted below summarizes the study:



The Study Identification Period is the time period eligibility to select patients who initiated treatment from December 2017 until approximately 200 patients have been enrolled.

Who can take part in the study?	<p>To be part of the study, participant must fulfill several conditions including the following:</p> <ul style="list-style-type: none"> Must be aged 18 or older at the time of first-line treatment initiation for mNSCLC. Must have initiated a first systemic treatment line for the mNSCLC from 1st December 2017. Must have signed Informed Consent Form or non-opposition to study participation.
---------------------------------	--

Clinical Study identification	
Protocol Number	NIS12500
Protocol Version	2.0 dated 10 December 2021
Full study title	An observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.
Registry ID	NCT05546905
Who sponsors this study?	
Name and contact details of the sponsor	Pierre Fabre Médicament Les Cauquillous 81500 Lavaur-France
Additional Information	

Glossary	
First line treatment	Initial, preferred or best treatment for a disease.
Second line treatment	Effective treatment administrated when the first line treatment may not work, may start but then stop working or may cause serious side effects.
Retrospective enrollment	Enrollment in the study conducted after treatment initiation.
Prospective enrollment	Enrollment in the study conducted at or before treatment initiation.
Informed Consent Form	A document in which patients are given important information in easy-to-understand language, including possible risks and benefits, about a medical procedure or treatment, genetic testing, or a clinical trial. This is to help them decide if they want to be treated, tested, or take part in the trial. Patients are also given any new information that might affect their decision to continue.